The role of Project 1 is to develop and test new chemistries to analyze mutation deletion and mrna expression by hybridization in the 96 well microarray format.
Specific aim 1 is focused on oligonucleotide probe chemistry, to enhance the selectivity and affinity of target binding. We emphasize new chemistries which we have begun to develop: peptide- probe chimera and probes employing branched AAP backbone chemistry.
This aim relies on modeling of mismatched duplex domains by Project 2.
Specific Aim 2 is focused on systematic (combinatorial) variation of surface chemistry, so as to exploit ling range interactions between the hybridization surface and solution state nucleic acid targets. This work is driven by collaboration with the surface modeling group of Project 2.
Specific Aim 3 will implement published fluorescence and chemiluminescent labeling methods, and will develop new lanthanide based fluorescence approaches which are matched to the special characteristics of the proximal CCD detection method od Project 3. In collaboration with Cores A&B, Specific Aim 3 also involves investigation of methods to achieve MRNA and DNA amplification especially those methods which can be automated.
Specific Aim 4 is focused on the development of quantitative high molecular weight target binding assays, employing RNA and DNA from well characterized tumor cell lines. We will use these assays to evaluate probe, surface and labeling chemistry improvements, on the workstations of Core A.
In Specific Aims 5 &6, we will analyze RNA and DNA from the highly characterized, nearly homogenous, library of lung tumor samples obtained from Core B. Core A facilities will be used to test advancements in probe, surface, labeling and detection, on RBA and DNA from those Core B tumor samples. These two aims involve identifying gene targets to be used as models for analysis of point mutation, LOH, mRNA expression and splicing as lung tumor biomarkers. The choice of these model loci and the process of designing the corresponding oligonucleotide probe sets ( for fabrication as microarrays in Core A) is performed in very close collaboration with the molecular biologists of Core B.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA074173-02
Application #
6103347
Study Section
Project Start
1999-04-20
Project End
1999-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Wang, X; Wang, L; Callister, M D et al. (2001) Human Rad17 is phosphorylated upon DNA damage and also overexpressed in primary non-small cell lung cancer tissues. Cancer Res 61:7417-21
Soria, J C; Moon, C; Wang, L et al. (2001) Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst 93:1257-63
Jang, S J; Soria, J C; Wang, L et al. (2001) Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res 61:7959-63
Wu, W G; Soria, J C; Wang, L et al. (2000) TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer. Anticancer Res 20:4525-9
Soria, J C; Jang, S J; Khuri, F R et al. (2000) Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 60:4000-4
Jang, S J; Mao, L (2000) Methylation patterns in human androgen receptor gene and clonality analysis. Cancer Res 60:864-6
Wang, L; Lin, S H; Wu, W G et al. (2000) C-CAM1, a candidate tumor suppressor gene, is abnormally expressed in primary lung cancers. Clin Cancer Res 6:2988-93
Jing, N; De Clercq, E; Rando, R F et al. (2000) Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. A basis for anti-HIV drug design. J Biol Chem 275:3421-30
Wu, W; Kemp, B L; Proctor, M L et al. (1999) Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer. Cancer Res 59:1846-51
Wu, W; Fan, Y H; Kemp, B L et al. (1998) Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res 58:4082-5